AgingResearch.NewsJoin free

Syndax Pharmaceuticals

CompanyUnited StatesFounded 2005

RORWikidata

Syndax Pharmaceuticals develops 2 assets, the furthest approved (Niktimvo in chronic graft versus host disease). Mostly antibody and small molecule acting on CSF1R, KMT2A and MEN1; based in the United States, founded in 2005.

2
Assets
Furthest stage
Approved
Raised
$144M
21
Trials
4
Signals

Pipeline

2

  • Niktimvo

    Blocks colony stimulating factor-1 receptor signaling to reduce pathogenic macrophage activity in chronic graft-versus-host disease.

    Approved, Antibody, CSF1R, chronic graft versus host disease, idiopathic pulmonary fibrosis (Phase 2)

  • revumenib

    Inhibits menin to disrupt oncogenic transcription driven by KMT2A rearrangements.

    Approved, Small molecule, KMT2A, MEN1, relapsed or refractory acute leukemia with a KMT2A translocation, Refractory Acute Leukemia

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Trials43
  • Funding rounds and grants12
  • Signals5
  • Similar companies6

Intelligence